Antiplatelet and anticoagulant therapy in patients with gastrointestinal bleeding: An 86-year-old woman with peptic ulcer disease

JAMA

Volumn 306, Issue 21, 2011, Pages 2367-2374

  Almadi, Majid A ^a   Barkun, Alan ^b   Brophy, James ^b  

^a KING KHALID UNIVERSITY HOSPITAL   (Saudi Arabia)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DABIGATRAN; ESOMEPRAZOLE; FAMOTIDINE; HEMOGLOBIN; HISTAMINE H2 RECEPTOR ANTAGONIST; MISOPROSTOL; PANTOPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; WARFARIN;

AGED; ANTICOAGULANT THERAPY; BRAIN HEMORRHAGE; CASE REPORT; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DIAPHORESIS; DIARRHEA; DIGITAL RECTAL EXAMINATION; DIZZINESS; DOSE RESPONSE; DRUG INHIBITION; DRUG MEGADOSE; DRUG WITHDRAWAL; DUODENUM ULCER; EPIDEMIOLOGICAL DATA; EPIGASTRIC DISCOMFORT; ERYTHROCYTE TRANSFUSION; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; HYPERTHERMIC THERAPY; INTERNATIONAL NORMALIZED RATIO; INTRAOCULAR HEMORRHAGE; LEUKOCYTE COUNT; LOW DRUG DOSE; MELENA; MONOTHERAPY; MUSCLE BLEEDING; PEPTIC ULCER; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; RETROPERITONEAL HEMORRHAGE; RISK FACTOR; RISK REDUCTION; STOMACH ULCER; STROKE; SYSTEMATIC REVIEW; THROMBOCYTE COUNT;

EID: 83055182078     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.1653     Document Type: Conference Paper

References (79)

1. Atkins D, Best D, Briss PA, et al. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ. 2004;328(7454):1490.
2. Lassen A, Hallas J, Schaffalitzky de Muckadell OB. Complicated and uncomplicated peptic ulcers in a Danish county 1993-2002: a population-based cohort study. Am J Gastroenterol. 2006;101(5):945-953. (Pubitemid 43725306)
3. Lewis JD, Bilker WB, Brensinger C, Farrar JT, Strom BL. Hospitalization and mortality rates from peptic ulcer disease and GI bleeding in the 1990s: relationship to sales of nonsteroidal anti-inflammatory drugs and acid suppression medications. Am J Gastroenterol. 2002;97(10):2540-2549.
4. Barkun AN, Bardou M, Kuipers EJ, et al. International Consensus Upper Gastrointestinal Bleeding Conference Group. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med. 2010;152(2):101-113.
5. van Leerdam ME, Vreeburg EM, Rauws EA, et al. Acute upper GI bleeding: did anything change? time trend analysis of incidence and outcome of acute upper GI bleeding between 1993/1994 and 2000. Am J Gastroenterol. 2003;98(7): 1494-1499. (Pubitemid 36875338)
6. Targownik LE, Nabalamba A. Trends in management and outcomes of acute nonvariceal upper gastrointestinal bleeding: 1993-2003. Clin Gastroenterol Hepatol. 2006;4(12):1459-1466.
7. Hearnshaw SA, Logan RF, Lowe D, Travis SP, Murphy MF, Palmer KR. Use of endoscopy for management of acute upper gastrointestinal bleeding in the UK: results of a nationwide audit. Gut. 2010;59(8):1022-1029.
8. Barkun A, Sabbah S, Enns R, et al. RUGBE Investigators. The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): endoscopic hemostasis and proton pump inhibition are associated with improved outcomes in a real-life setting. Am J Gastroenterol. 2004;99(7):1238- 1246.
9. Hearnshaw SA, Logan RF, Lowe D, Travis SP, Murphy MF, Palmer KR. Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit. Gut. 2011;60(10):1327-1335.
10. Laine L. Review article: gastrointestinal bleeding with low-dose aspirin-what's the risk? Aliment Pharmacol Ther. 2006;24(6):897-908. (Pubitemid 44326371)
11. Serebruany VL, Malinin AI, Eisert RM, Sane DC. Risk of bleeding complications with antiplatelet agents: meta-analysis of 338 191 patients enrolled in 50 randomized controlled trials. Am J Hematol. 2004;75(1):40-47. (Pubitemid 38040166)
12. Hallas J, Dall M, Andries A, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based casecontrol study. BMJ. 2006;333(7571):726.
13. Huang ES, Strate LL, Ho WW, Lee SS, Chan AT. Long-term use of aspirin and the risk of gastrointestinal bleeding. Am J Med. 2011;124(5):426-433.
14. Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med. 2002;346(26):2033-2038. (Pubitemid 34680594)
15. Cryer B. Reducing the gastrointestinal risks of low-dose aspirin. Gastroenterology. 2010;138(1):30-33.
16. Ng FH, Wong SY, Chang CM, et al. High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease. Aliment Pharmacol Ther. 2003;18(4):443-449. (Pubitemid 37070243)
17. Hansen ML, Sørensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010;170(16):1433-1441.
18. Yeomans ND, Lanas AI, Talley NJ, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther. 2005;22(9):795-801. (Pubitemid 41564359)
19. Bhatt DL, Scheiman J, Abraham NS, et al. American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. ACCF/ACG/ AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2008;52(18):1502-1517.
20. García Rodríguez LA, Lin KJ, Hernández-Díaz S, Johansson S. Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. Circulation. 2011;123(10):1108- 1115.
21. Saini SD, Fendrick AM, Scheiman JM. Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention. Aliment Pharmacol Ther. 2011;34(2):243-251.
22. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel vs aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348(9038): 1329-1339.
23. Berger PB, Bhatt DL, Fuster V, et al. CHARISMA Investigators. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation. 2010;121(23):2575-2583.
24. Delaney JA, Opatrny L, Brophy JM, Suissa S. Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ. 2007; 177(4):347-351. (Pubitemid 47339530)
25. Lanas A, García-Rodríguez LA, Arroyo MT, et al. Investigators of the Asociación Española de Gastroenterologí a. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol. 2007;102(3):507- 515.
26. Usman MH, Notaro LA, Nagarakanti R, et al. Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble?AmJ Cardiol. 2009;103(8):1107-1112.
27. Diener HC, Bogousslavsky J, Brass LM, et al. MATCH Investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, doubleblind, placebo-controlled trial. Lancet. 2004;364(9431):331-337.
28. Bhatt DL, Fox KA, Hacke W, et al. CHARISMA Investigators. Clopidogrel and aspirin vs aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706-1717.
29. van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest. 2006;129(5):1155-1166.
30. Wiedermann CJ, Stockner I. Warfarin-induced bleeding complications- clinical presentation and therapeutic options. Thromb Res. 2008;122(suppl 2): S13-S18. (Pubitemid 351783319)
31. Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3)(suppl):287S-310S. (Pubitemid 39297958)
32. DeEugenio D, Kolman L, DeCaro M, et al. Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy. Pharmacotherapy. 2007;27(5): 691-696. (Pubitemid 46700961)
33. Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY Steering Committee and Investigators. Dabigatran vs warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151.
34. Wann LS, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2011;57 (11):1330-1337.
35. Connolly SJ, Pogue J, Hart RG, et al. ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009; 360(20):2066-2078.
36. Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011; 154(1):1-11.
37. Biondi-Zoccai GG, Lotrionte M, Agostoni P, et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50 279 patients at risk for coronary artery disease. Eur Heart J. 2006;27(22): 2667-2674. (Pubitemid 44729867)
38. Burger W, Chemnitius JM, Kneissl GD, Rücker G. Low-dose aspirin for secondary cardiovascular prevention-cardiovascular risks after its perioperative withdrawal vs bleeding risks with its continuation-review and meta-analysis. J Intern Med. 2005;257(5):399-414. (Pubitemid 40604544)
39. Sung JJ, Lau JY, Ching JY, et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med. 2010;152(1):1-9.
40. Barkun AN, Bardou M. Aspirin withdrawal in acute peptic ulcer bleeding: are we harming patients? Ann Intern Med. 2010;152(1):52-53, W-12.
41. Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA. ACCF/ACG/ AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol. 2010;105(12):2533-2549.
42. Wolf AT, Wasan SK, Saltzman JR. Impact of anticoagulation on rebleeding following endoscopic therapy for nonvariceal upper gastrointestinal hemorrhage. Am J Gastroenterol. 2007;102(2):290-296. (Pubitemid 46160542)
43. Baradarian R, Ramdhaney S, Chapalamadugu R, et al. Early intensive resuscitation of patients with upper gastrointestinal bleeding decreases mortality. Am J Gastroenterol. 2004;99(4):619-622. (Pubitemid 38607962)
44. Choudari CP, Rajgopal C, Palmer KR. Acute gastrointestinal haemorrhage in anticoagulated patients: diagnoses and response to endoscopic treatment. Gut. 1994;35(4):464-466. (Pubitemid 24131240)
45. Taha AS, McCloskey C, Prasad R, Bezlyak V. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet. 2009; 374(9684):119-125.
46. Yeomans N, Lanas A, Labenz J, et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol. 2008;103(10):2465-2473.
47. Ng FH, Wong SY, Lam KF, et al. Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology. 2010;138(1):82-88.
48. Hsiao FY, Tsai YW, Huang WF, et al. A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding. Clin Ther. 2009; 31(9):2038-2047.
49. Rostom A, Dube C, Wells G, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev. 2002;(4):CD002296.
50. Chan FK, Chung SC, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking lowdose aspirin or naproxen. N Engl J Med. 2001;344(13):967-973. (Pubitemid 32240315)
51. Hsu PI, Lai KH, Liu CP. Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis. Gastroenterology. 2011;140(3):791-798.
52. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302(8):849-857.
53. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360(4):354-362.
54. Simon T, Verstuyft C, Mary-Krause M, et al. French Registry of Acute STElevation and Non-ST-Elevation Myocardial Infarction Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4):363-375.
55. Simon T, Steg PG, Gilard M, et al. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry. Circulation. 2011;123(5):474-482.
56. Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost. 2007;5(12):2429-2436. (Pubitemid 350154353)
57. Kim KA, Park PW, Hong SJ, Park JY. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther. 2008;84(2):236-242.
58. Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol. 2008;48(4):475-484. (Pubitemid 351389118)
59. O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009;374(9694):989- 997.
60. Lima JP, Brophy JM. The potential interaction between clopidogrel and proton pump inhibitors: a systematic review. BMC Med. 2010;8(1):81.
61. Kwok CS, Yeong JK, Loke YK. Meta-analysis: risk of fractures with acidsuppressing medication. Bone. 2011;48(4):768-776.
62. Blackburn DF, Lamb DA, Mcleod MM, Eurich DT. Increased use of acidsuppressing drugs before the occurrence of ischemic events: a potential source of confounding in recent observational studies. Pharmacotherapy. 2010;30(10): 985-993.
63. US Food and Drug Administration. FDA Drug safety communication: reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. March 12, 2010. http://www.fda.gov/Drugs/DrugSafety /PostmarketDrugSafetyInformationforPatientsandProviders/ucm203888.htm. Accessed September 25, 2011.
64. Charlot M, Grove EL, Hansen PR, et al. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ. 2011;342:d2690.
65. Adamopoulos AB, Sakizlis GN, Nasothimiou EG, et al. Do proton pump inhibitors attenuate the effect of aspirin on platelet aggregation? a randomized crossover study. J Cardiovasc Pharmacol. 2009;54(2):163-168.
66. de Aquino Lima JP, Brophy JM. Conflicting evidence: what's a clinician to do? Ann Intern Med. 2010;153(6):413-415.
67. Lau JY, Sung J, Hill C, Henderson C, Howden CW, Metz DC. Systematic review of the epidemiology of complicated peptic ulcer disease: incidence, recurrence, risk factors and mortality. Digestion. 2011;84(2):102-113.
68. Takahashi M, Kawabe T, Ogura K, et al. Expression of vascular endothelial growth factor at the human gastric ulcer margin and in cultured gastric fibroblasts: a new angiogenic factor for gastric ulcer healing. Biochem Biophys Res Commun. 1997;234(2):493-498. (Pubitemid 27243932)
69. Whittle BJ. Arachidonic acid metabolites and the gastro-intestinal toxicity of anti-inflammatory agents. Prostaglandins. 1981;21(suppl):113-118. (Pubitemid 11019544)
70. Arisawa T, Tahara T, Shibata T, et al. Association between genetic polymorphisms in the cyclooxygenase-1 gene promoter and peptic ulcers in Japan. Int J Mol Med. 2007;20(3):373-378.
71. Shiotani A, Sakakibara T, Nomura M, et al. Aspirin-induced peptic ulcer and genetic polymorphisms. J Gastroenterol Hepatol. 2010;25(suppl 1):S31-S34.
72. Lu CC, Sheu BS, Chen TW, et al. Host TNF-α-1031 and -863 promoter single nucleotide polymorphisms determine the risk of benign ulceration after H pylori infection. Am J Gastroenterol. 2005;100(6):1274-1282.
73. Marcil V, Seidman E, Sinnett D, et al. Modification in oxidative stress, inflammation, and lipoprotein assembly in response to hepatocyte nuclear factor 4α knockdown in intestinal epithelial cells. J Biol Chem. 2010;285(52):40448-40460.
74. Cairns JA, Connolly S, McMurtry S, Stephenson M, Talajic M; CCS Atrial Fibrillation Guidelines Committee. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol. 2011;27(1):74-90.
75. Friberg L, Hammar N, Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. Eur Heart J. 2010;31 (8):967-975.
76. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864-2870. (Pubitemid 32537350)
77. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010; 137(2):263-272.
78. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel userfriendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093-1100.
79. Hernández-Díaz S, García Rodríguez LA. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med. 2006; 4:22.